Definium Therapeutics Reports Statistically Significant Phase 3 Results for DT120 ODT in Generalized Anxiety Disorder
Market Chameleon (Wed, 12-Aug 11:13 AM)
Definium's DT120 ODT Delivers Strong Efficacy in Phase 3 GAD Study—A New Standard for Anxiety Treatment?
Market Chameleon (Wed, 12-Aug 7:56 AM)
Definium Therapeutics Launches ‘Wired for Worry’, Addressing Critical Gaps in GAD Awareness and Clinical Tools
Market Chameleon (Thu, 16-Jul 7:06 AM)
